TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7930542

Group type: EXPERIMENTAL
Intervention: Prophylactic ampicillin/sulbactam
Number of subjects: 128

Group type: COMPARATOR
Intervention: Gentamicin and metronidazole
Number of subjects: 128
Study: 2905387

Group type: EXPERIMENTAL
Intervention: Low dosage chlorthalidone
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 29973251

Group type: EXPERIMENTAL
Intervention: Authentic N95 facemasks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham N95 facemasks
Number of subjects: 15
Study: 27479536

Group type: EXPERIMENTAL
Intervention: Next-step treatment for MDD after failing initial antidepressant trial
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Next-step treatment for MDD
Number of subjects: 1522
Study: 25799445

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) and facial mask (FM) therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG) - untreated Class III patients
Number of subjects: 21
Study: 23865512

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (sham acupressure)
Number of subjects: 90
Study: 21083927

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (warfarin therapy based on algorithms using clinical information and genotypes for polymorphisms in CYP2C9 and VKORC1)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Clinical-guided dosing (warfarin therapy based on algorithms using only clinical information)
Number of subjects: 1238
Study: 18757777

Group type: EXPERIMENTAL
Intervention: PET(−) patients
Number of subjects: 817

Group type: COMPARATOR
Intervention: PET(+) patients
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 817
Study: 16369994

Group type: EXPERIMENTAL
Intervention: Tamoxifen or toremifene alone or in combination with chemotherapy (either concurrently or sequentially)
Number of subjects: 4948

Group type: COMPARATOR
Intervention: Hormonal therapy alone (tamoxifen or toremifene)
Number of subjects: 4948

Group type: COMPARATOR
Intervention: No chemotherapy or beyond 3 months after completing chemotherapy
Number of subjects: 4948

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 4948

Group type: COMPARATOR
Intervention: Hormonal therapy
Number of subjects: 4948
Study: 14659376

Group type: EXPERIMENTAL
Intervention: Randomised controlled trial (RConT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised comparison trial (RComT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other experimental designs
Number of subjects: 0
Study: 10817373

Group type: EXPERIMENTAL
Intervention: True provocation to electric and magnetic fields
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sham provocation to electric and magnetic fields
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study: 8941016

Group type: EXPERIMENTAL
Intervention: Overt testicular leukemia
Number of subjects: 651

Group type: COMPARATOR
Intervention: No overt testicular leukemia
Number of subjects: 651
Study: 1512327

Group type: EXPERIMENTAL
Intervention: Heparin therapy (5,000 U bolus followed by 1,000 U/h continuous infusion)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Heparin therapy (optimal anticoagulation)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Heparin therapy (suboptimal anticoagulation)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Heparin therapy (inadequate anticoagulation)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 281
Study: 6527973

Group type: EXPERIMENTAL
Intervention: 2.5mg intravenous nicardipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10mg intravenous nicardipine
Number of subjects: 20
Study: 31805981

Group type: EXPERIMENTAL
Intervention: Resistance and aerobic and functional exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional program including only resistance and aerobic exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care program
Number of subjects: 0
Study: 30442501

Group type: COMPARATOR
Intervention: dinutuximab beta alone
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: dinutuximab beta with subcutaneous IL-2
Number of subjects: 406
Study: 26846357

Group type: EXPERIMENTAL
Intervention: Active supplementation (encapsulated fruit and vegetable powder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25180702

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (15-20 minutes, up to 6 times weekly for 12 months)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 340
Study: 22160145

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Darunavir/ritonavir triple therapy
Number of subjects: 225
Study: 20813583

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (maximum 3mg/24h)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 67
Study: 17430326

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Granisetron-dexamethasone combination (granisetron 40 microg/kg and dexamethasone 150 microg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study: 15478386

Group type: EXPERIMENTAL
Intervention: Active cough treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline sessions (days 1 and 2)
Number of subjects: 28
Study: 11892004

Group type: EXPERIMENTAL
Intervention: KneeNavTM ACL (computer-assisted surgical navigation technique)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional arthroscopic technique
Number of subjects: 20
Study: 9506736

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Suppressive doses of L‐T4
Number of subjects: 50
Study: 7871648

Group type: EXPERIMENTAL
Intervention: Cavinton
Number of subjects: 133

Group type: COMPARATOR
Intervention: HBsAg carriers
Number of subjects: 133

Group type: COMPARATOR
Intervention: Patients with chronic diffuse liver diseases
Number of subjects: 133

Group type: COMPARATOR
Intervention: Patients with uveitis
Number of subjects: 133
Study: 3411388

Group type: COMPARATOR
Intervention: Food hypersensitivity evaluation through double-blind placebo-controlled food challenges
Number of subjects: 46

Group type: COMPARATOR
Intervention: Food challenges
Number of subjects: 46

Group type: COMPARATOR
Intervention: Food hypersensitivity reactions (egg, milk, peanut)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Symptoms during food challenges
Number of subjects: 46
Study: 30704923

Group type: EXPERIMENTAL
Intervention: Eltrombopag 200 mg (100 mg for east Asians) once daily during induction chemotherapy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 148
Study: 28641384

Group type: EXPERIMENTAL
Intervention: Lupron® injections (7.5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lupron and testosterone (L+T) replacement for 49 days
Number of subjects: 32
Study: 27131419

Group type: EXPERIMENTAL
Intervention: Neostigmine 40μg.kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine 20μg.kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine 10μg.kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with atropine
Number of subjects: 60
Study: 24403557

Group type: EXPERIMENTAL
Intervention: JS7 DNA vaccine and MVA/HIV62B (DDMM regimen)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: MVA/HIV62B (MMM regimen)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 299
Study: 22275160

Group type: EXPERIMENTAL
Intervention: Fasudil 40 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fasudil 80 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fasudil (40 mg or 80 mg)
Number of subjects: 17
Study: 19382501

Group type: EXPERIMENTAL
Intervention: Topically applied mytomycin-C (MMC) for 5 minutes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal saline (control) for 5 minutes
Number of subjects: 38
Study: 17893256

Group type: EXPERIMENTAL
Intervention: Ex-leg (exercising leg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Rest-leg (resting leg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Circulating IGFBP-1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 7
Study: 14705120

Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation
Number of subjects: 16
Study: 11459446

Group type: EXPERIMENTAL
Intervention: Likelihood‐based repeated measures analyses (MMRM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Last observation carried forward approach (LOCF)
Number of subjects: 0
Study: 10448446

Group type: EXPERIMENTAL
Intervention: Volunteer befriending intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study: 7602350

Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m2 by 24-hour continuous intravenous infusion with mesna on day 1, carboplatin 300 mg/m2 intravenously on day 1, etoposide 50 mg/m2 orally on days 1 to 21 every 4 weeks (schedule I)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ifosfamide 3.75 g/m2 IV on day 1, carboplatin 300 mg/m2 IV on day 1, etoposide 50 mg orally on days 1 to 14 (schedule II)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall treatment (ICE regimen)
Number of subjects: 35
Study: 2085990

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 grams, single dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg b.i.d. for 7 days)
Number of subjects: 60
Study: 282070

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, orally)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine (sublingual route)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nifedipine (in five patients with hypertensive crisis)
Number of subjects: 27
Study: 31207253

Group type: EXPERIMENTAL
Intervention: High soy protein (HSP; 50 g)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low soy protein (LSP; 25 g)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (CON; 50 g carbohydrate)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin response
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Leptin response
Number of subjects: 17
Study: 28182508

Group type: EXPERIMENTAL
Intervention: CHOI
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CHOR
Number of subjects: 14

Group type: COMPARATOR
Intervention: PLAI
Number of subjects: 14

Group type: COMPARATOR
Intervention: PLAR
Number of subjects: 14
Study: 25991760

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (CRYO)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard major haemorrhage therapy (STANDARD)
Number of subjects: 43
Study: 23795754

Group type: EXPERIMENTAL
Intervention: PCR-IAP
Number of subjects: 229

Group type: COMPARATOR
Intervention: IAP
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Phase 2 PCR assay
Number of subjects: 229
Study: 22664119

Group type: EXPERIMENTAL
Intervention: Deferiprone 75 mg/kg/day TDS orally with deferoxamine 30-50 mg/kg subcutaneously every other day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Deferoxamine 30-50 mg/kg/day subcutaneously for 6-12 hours/day and 5-6 days per week
Number of subjects: 26
Study: 19097925

Group type: EXPERIMENTAL
Intervention: PDA-based system
Number of subjects: 93

Group type: COMPARATOR
Intervention: Paper-based system
Number of subjects: 93
Study: 17524772

Group type: EXPERIMENTAL
Intervention: Tunneled scleral incision
Number of subjects: 88

Group type: COMPARATOR
Intervention: Straight scleral injection
Number of subjects: 88
Study: 15374722

Group type: EXPERIMENTAL
Intervention: Endometrial laser intrauterine thermal therapy (ELITT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Transcervical hysteroscopic endometrial resection (TCRE)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both ELITT and TCRE
Number of subjects: 116
Study: 11583481

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9539615

Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS) 6% i.v. at 15 mL/kg up to 1000 mL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) 6% i.v. at 15 mL/kg up to 1000 mL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 32
Study: 7855219

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/kg naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control infusions
Number of subjects: 0
Study: 2680086

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 351232

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30671872

Group type: EXPERIMENTAL
Intervention: Two-hourly repositioning 24/7
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alternating pressure air mattress (recommended intervention)
Number of subjects: 80
Study: 28815282

Group type: EXPERIMENTAL
Intervention: 20 μg/day calcidiol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 40 μg/day calcidiol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 125 μg/week calcidiol
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All dosages of calcidiol
Number of subjects: 87
Study: 25422394

Group type: EXPERIMENTAL
Intervention: Water treatment
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Sanitation and latrine improvements
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Combination of all three interventions
Number of subjects: 499
Study: 23742346

Group type: EXPERIMENTAL
Intervention: Facade insulation measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16446335

Group type: EXPERIMENTAL
Intervention: Structured multidisciplinary intervention (eight 90-minute sessions)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 103
Study: 15089797

Group type: EXPERIMENTAL
Intervention: Diabetes nurse educational programme (DN group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (UC group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups at 18 months
Number of subjects: 54
Study: 11254020

Group type: EXPERIMENTAL
Intervention: Inositol (12 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (D-glucose)
Number of subjects: 24
Study: 9273228

Group type: EXPERIMENTAL
Intervention: Noise exposure (over 90 dB intensity)
Number of subjects: 2599

Group type: COMPARATOR
Intervention: Control group (not exposed to noise)
Number of subjects: 2599
Study: 1622644

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for 2 or 5 years)
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1347
Study: 6469811

Group type: EXPERIMENTAL
Intervention: Humidified room-temperature air containing 0.5 ppm SO2
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cold dry air
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cold dry air containing 0.5 ppm SO2
Number of subjects: 7
Study: 31282542

Group type: EXPERIMENTAL
Intervention: Dipyridamole (100 mg 4 times a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31322200

Group type: EXPERIMENTAL
Intervention: Spirulina, curcumin, and Boswellia supplement
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28425818

Group type: EXPERIMENTAL
Intervention: 3-dose priming and booster (3 + 1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 2-dose priming and booster (2 + 1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 3-dose priming without booster (3 + 0)
Number of subjects: 300
Study: 26521589

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neiguan (PC 6) 30 min before operation until the end of operation.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture).
Number of subjects: 50
Study: 23398709

Group type: EXPERIMENTAL
Intervention: Participatory behavior‐based injury prevention approach integrated with safety culture initiatives
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Owner/manager led constructive dialogue meetings with workers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intervention enterprises
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison enterprises
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both intervention and comparison enterprises
Number of subjects: 16
Study: 21481274

Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Self-Management Program (including three face-to-face sessions, telephone and text messaging follow-up)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 19249750

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16482753

Group type: EXPERIMENTAL
Intervention: Morbidity-last group (questions about the wife's disease first)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Morbidity-first group (respondent's current wellbeing first)
Number of subjects: 76
Study: 12617375

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) combined with standard physiotherapy (10 cycles of 3 minutes with a peak of 40 mmHg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment (sham short-wave therapy for 30 minutes) combined with conventional physiotherapy
Number of subjects: 23
Study: 10875524

Group type: EXPERIMENTAL
Intervention: Experimental Sorting Task for Children (STC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Modified Card Sorting Test (adult sorting task)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pilot study of children with idiopathic or cryptogenic epilepsy
Number of subjects: 64
Study: 8699499

Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 2
Study: 1394828

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Epodyl
Number of subjects: 777

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: 4-epirubicin
Number of subjects: 777

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 777
Study: 4074992

Group type: EXPERIMENTAL
Intervention: Cognitive control methods through a detailed booklet (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive control methods taught orally (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Attention-placebo control group (group 3)
Number of subjects: 30
Study: 31697747

Group type: EXPERIMENTAL
Intervention: Simulated left/right Kocher-Monro trajectory
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 132
Study: 28722030

Group type: EXPERIMENTAL
Intervention: legume-based TLC diet
Number of subjects: 31

Group type: COMPARATOR
Intervention: legume-free TLC diet
Number of subjects: 31
Study: 27048747

Group type: EXPERIMENTAL
Intervention: MVC + 2 N(t)RTI
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: MVC + PI/r
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control (current combination antiretroviral therapy)
Number of subjects: 395
Study: 25149882

Group type: EXPERIMENTAL
Intervention: INSURE method (Intubation, Surfactant administration and extubation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Mechanical Ventilation (CMV)
Number of subjects: 0
Study: 22078337

Group type: EXPERIMENTAL
Intervention: Trigone-including injections of 500 U abobotulinumtoxinA diluted to 20ml
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trigone-sparing injections of 500 U abobotulinumtoxinA diluted to 20ml
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Trigone-including injections
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Trigone-including and trigone-sparing injections
Number of subjects: 22
Study: 20008446

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 17617524

Group type: EXPERIMENTAL
Intervention: Conservative surgery (unilateral salpingo-oophorectomy or cystectomy) for stage I disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, etc.) for advanced-stage disease or completed childbearing
Number of subjects: 0
Study: 16116013

Group type: EXPERIMENTAL
Intervention: Lightwand (Intubating Lighted Stylet)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Macintosh laryngoscopy
Number of subjects: 36

Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 36
Study: 11821289

Group type: EXPERIMENTAL
Intervention: Serum IL-6
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PF TNF-alpha
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (tubal ligation or reanastomosis)
Number of subjects: 130
Study: 10029400

Group type: EXPERIMENTAL
Intervention: Pacifier with sucrose
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Pacifier with sterile water
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 122